Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)

NCT06630325 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT06630325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART): Adaptive Clinical Treatment (ACT)
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
June 24, 2025
Completion date
March 11, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast carcinoma, advanced malignant solid neoplasm, advanced ovarian carcinoma, advanced pancreatic carcinoma, advanced prostate carcinoma, advanced sarcoma, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv prostate cancer ajcc v8